Steven Kelly joins Theracrine as CEO
This article was originally published in Scrip
Executive Summary
Theracrine, a biopharmaceutical company developing novel therapeutics to treat metastatic cancer, has appointed Steven Kelly president and CEO. Mr Kelly most recently served as chief commercial officer for BioVex, which was sold to Amgen this year. He was previously the founder and CEO of Innovive Pharmaceuticals.